Overview

Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia

Status:
NOT_YET_RECRUITING
Trial end date:
2026-11-24
Target enrollment:
Participant gender:
Summary
This is a clinical study on the use of iNK cells for the treatment of refractory relapsed acute myeloid leukemia.
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
Guangzhou Ruixin Biotechnological Co., LTD
Collaborator:
Fifth Affiliated Hospital of Guangzhou Medical University